Genmab A/S Sponsored ADR (NASDAQ:GMAB) Given Average Rating of “Moderate Buy” by Analysts

Shares of Genmab A/S Sponsored ADR (NASDAQ:GMAB) have been assigned a consensus recommendation of “Moderate Buy” from the ten ratings firms that are presently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation and six have given a buy recommendation to the company. The average 1 year target price among brokerages that have updated their coverage on the stock in the last year is $39.25.

Several equities analysts have issued reports on GMAB shares. Johnson Rice reiterated a “buy” rating on shares of Genmab A/S in a research report on Monday, October 27th. Zacks Research cut Genmab A/S from a “strong-buy” rating to a “hold” rating in a report on Friday, October 31st. Wall Street Zen upgraded Genmab A/S from a “hold” rating to a “buy” rating in a report on Saturday, November 22nd. Truist Financial reaffirmed a “buy” rating and set a $48.00 price target (down previously from $49.00) on shares of Genmab A/S in a research note on Thursday, November 6th. Finally, HC Wainwright cut their price target on shares of Genmab A/S from $41.00 to $39.00 and set a “buy” rating on the stock in a report on Tuesday.

Institutional Trading of Genmab A/S

Hedge funds and other institutional investors have recently modified their holdings of the business. Wealth Enhancement Advisory Services LLC acquired a new position in shares of Genmab A/S in the 2nd quarter worth approximately $257,000. Park Avenue Securities LLC boosted its holdings in Genmab A/S by 5.9% in the second quarter. Park Avenue Securities LLC now owns 14,940 shares of the company’s stock worth $309,000 after purchasing an additional 832 shares during the period. Eagle Global Advisors LLC increased its stake in Genmab A/S by 0.5% during the second quarter. Eagle Global Advisors LLC now owns 210,295 shares of the company’s stock valued at $4,345,000 after purchasing an additional 1,000 shares during the last quarter. DAVENPORT & Co LLC increased its stake in Genmab A/S by 6.8% during the second quarter. DAVENPORT & Co LLC now owns 33,826 shares of the company’s stock valued at $699,000 after purchasing an additional 2,147 shares during the last quarter. Finally, Callan Family Office LLC acquired a new stake in shares of Genmab A/S during the second quarter worth $655,000. 7.07% of the stock is owned by hedge funds and other institutional investors.

Genmab A/S Stock Performance

Shares of Genmab A/S stock opened at $33.88 on Friday. The company’s fifty day moving average is $32.17 and its two-hundred day moving average is $28.64. The company has a market capitalization of $21.76 billion, a P/E ratio of 14.42, a PEG ratio of 18.64 and a beta of 0.90. Genmab A/S has a 1 year low of $17.24 and a 1 year high of $35.43.

Genmab A/S (NASDAQ:GMAB) last posted its quarterly earnings data on Thursday, November 6th. The company reported $0.65 earnings per share for the quarter, topping analysts’ consensus estimates of $0.48 by $0.17. Genmab A/S had a return on equity of 23.98% and a net margin of 41.36%.The company had revenue of $1.02 billion during the quarter, compared to analysts’ expectations of $975.40 million. As a group, equities analysts expect that Genmab A/S will post 1.45 earnings per share for the current year.

About Genmab A/S

Genmab A/S is a Denmark-based biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has built a robust research platform focused on harnessing novel antibody engineering technologies to create next-generation therapies. The company’s work centers on identifying targets in hematologic malignancies and solid tumors, advancing its proprietary molecules from early discovery through clinical development.

Genmab’s portfolio includes products developed in collaboration with leading global pharmaceutical partners.